Highest-materiality recent filing
Abbott settles NEC litigation for $670M covering Gill case and ~2,000 infants
Agreements resolve $495M Gill verdict plus NEC claims for ~2,000 infants, total ~$670M.
Abbott Q2 adjusted EPS $1.31; raises FY2026 EPS guidance to $5.45-$5.60
Q2 reported sales $12.6B (+13.0% reported, +4.8% comparable); GAAP EPS $0.53, adjusted EPS $1.31.
Abbott adds Kevin Conroy to board; shareholders approve 2026 Incentive Stock Program
Kevin Conroy appointed to Abbott's Board of Directors effective April 24, 2026.
Settlement of consolidated derivative action alleging fiduciary breaches and securities violations related to infant formula recall.
Abbott Q1 adj. EPS $1.15, +6% YoY; acquires Exact Sciences; FY guidance $5.38-$5.58
Q1 GAAP diluted EPS $0.61; adjusted diluted EPS $1.15 (+6% YoY).
Abbott completes $105/share cash acquisition of Exact Sciences, expanding cancer diagnostics
Abbott completed acquisition of Exact Sciences for $105/share cash; Exact becomes wholly owned subsidiary.
Abbott completes $20B senior notes offering to fund Exact Sciences acquisition
Issued $20B in eight tranches: Floating Rate Notes due 2029, fixed-rate notes from 3.700% to 5.600% with maturities 2029–2066.
Abbott issues $20B multi-tranche notes; proceeds to fund Exact Sciences acquisition
Issued $20B in senior notes across 8 tranches: floating and fixed rates from 3.70% to 5.60%, maturities 2029-2066.
Abbott reduces board size from 13 to 12 directors effective April 24, 2026
Board of Directors amended Article III, Section 2 of By-Laws on February 20, 2026.
Abbott Q4 adj EPS $1.50 (+12% YoY); FY2025 revenue $44.3B; FY2026 adj EPS guide $5.55–$5.80
Q4 GAAP EPS $1.01, adjusted EPS $1.50 (+12% YoY); revenue $11.46B (+4.4% reported, +3.8% ex-COVID).
Abbott names Nita Ahuja to Board of Directors; board expands to 13 members
Nita Ahuja, M.D. appointed to Abbott’s Board of Directors effective December 12, 2025.
Abbott blackout period for retirement plan Dec 24 to Jan 11 due to admin changes
Blackout begins Dec 24, 2025 at 12pm CST, ends week of Jan 11, 2026.
Abbott to acquire Exact Sciences for $105/share, total equity value ~$21B
Abbot buys Exact Sciences for $105 per share in cash; equity value ~$21B, enterprise value ~$23B.
Abbott Q3 sales rise 6.9%; adj. EPS $1.30; reaffirms FY guidance
GAAP diluted EPS $0.94; adjusted diluted EPS $1.30; reported sales $11.37B, organic growth 5.5% (7.5% ex-COVID testing).
Abbott Q2 adjusted EPS $1.26, sales $11.14B (+7.4%); guides FY adjusted EPS $5.10-$5.20
GAAP diluted EPS $1.01; adjusted diluted EPS $1.26, double-digit growth YoY.
Abbott General Counsel Hubert L. Allen to retire after transition period
Hubert L. Allen, EVP, General Counsel and Secretary, notified Abbott on April 25, 2025 of his planned retirement.
Abbott annual meeting results: all directors elected, auditor ratified, say-on-pay approved
All 12 director nominees elected; Nancy McKinstry received 1.12B for vs 243.9M against (82%).
Abbott Q1 adjusted EPS $1.09, revenue $10.36B (+4% reported); reaffirms FY guidance
GAAP diluted EPS $0.76; adjusted diluted EPS $1.09 (double-digit YoY growth).
Abbott Q4 organic base business sales +10.1%; FY2025 adj. EPS guidance $5.05-$5.25
Q4 reported sales $11.0B (+7.2% YoY); organic base business (ex-COVID) grew 10.1%.
Abbott extends change-in-control agreements for NEOs through Dec 2026
Agreements previously set to expire Dec 31, 2024, now extended to Dec 31, 2026.
Abbott Q3 2024: GAAP EPS $0.94, adj. EPS $1.21; raises FY adj. EPS guidance midpoint
Reported sales $10.6B (+4.9% reported, +8.2% organic ex-COVID tests); Medical Devices +13.3% organic.
Abbott Q2 adjusted EPS $1.14, revenue $10.4B; raises FY guidance
GAAP EPS $0.74, adjusted $1.14; revenue $10.4B (+4% reported, +9.3% organic ex-COVID).
Abbott EVP Finance Robert Funck Jr. to retire July 1, 2024 after 36 years
Robert E. Funck Jr., Executive Vice President, Finance, plans to retire effective July 1, 2024.
Abbott annual meeting results elect board, ratify auditor, approve executive compensation
All 12 board nominees elected; Nancy McKinstry received ~242.6M against votes, John G. Stratton ~347.3M against.
Abbott Q1 adj. EPS $0.98; raises FY2024 midpoint guidance
Q1 GAAP diluted EPS $0.70; adjusted diluted EPS $0.98; revenue $9.96B (+2.2% reported).
Abbott enters new $5B unsecured revolving credit facility, terminates prior facility
New 5-year revolving credit agreement with JPMorgan Chase as agent, effective Jan 29, 2024.
Abbott Q4 adj EPS $1.19, base organic +11%; FY24 guide $4.50-$4.70
Q4 reported sales $10.241B (+1.5%); organic base business growth +11.0% excluding COVID tests.
Abbott Q3 adj EPS $1.14, rev $10.1B; raises FY23 EPS midpoint
Q3 GAAP EPS $0.82; adjusted EPS $1.14; reported sales $10.1B (-2.6% YoY).
Abbott amends 8-K to correct vote count against director Michael F. Roman
Corrected votes against Michael F. Roman: 25,575,883 (originally reported incorrectly).
Abbott Q2 2023: Sales $10B, adjusted EPS $1.08; underlying base organic growth 11.5%
Q2 GAAP diluted EPS $0.78; adjusted diluted EPS $1.08; revenue $9,978M, down 11.4% reported (COVID testing decline).
Abbott appoints new EVP Finance, CFO, and Controller effective September 1, 2023
Robert E. Funck, Jr. appointed Executive Vice President, Finance effective Sep 1, 2023.
Abbott Labs to hold annual say-on-pay vote after shareholder approval
Board determined to hold annual advisory vote on executive compensation, based on shareholder vote at April 28 annual meeting.
Director Nancy McKinstry received 329M against votes (24.6%); John Stratton received 373M against (27.9%).
Abbott Q1 revenue $9.7B, adj EPS $1.03; base business organic growth 10.0%
Q1 GAAP EPS $0.75; adjusted EPS $1.03; revenue $9.747B, down 18.1% reported, but organic base business up 10.0%.
Abbott reduces board size from 13 to 12, effective April 28, 2023
Board approved amendment to Article III, Section 2 of by-laws on Feb 17, 2023.
Abbott Q4 sales $10.1B, full-year GAAP EPS $3.91; guides FY23 adj. EPS $4.30-4.50
Q4 GAAP diluted EPS $0.59; adjusted diluted EPS $1.03; full-year GAAP EPS $3.91, adjusted $5.34.
Abbott amends by-laws to update shareholder nomination procedures and special meeting rules
Board amended and restated by-laws effective December 9, 2022.
Abbott extends change-in-control agreements with named executive officers through Dec 2024
Extension moves expiration date from Dec 31, 2022 to Dec 31, 2024 for named executive officers.
Abbott posts Q3 adj. EPS $1.15, revenue $10.4B; raises full-year EPS guidance
Q3 GAAP EPS $0.81, adjusted EPS $1.15; reported sales -4.7%, organic +1.3%.
Abbott appoints Claire Babineaux-Fontenot to Board; board size expanded to 13
Claire Babineaux-Fontenot named to Abbott's Board of Directors effective September 15, 2022.
Abbott Q2 EPS $1.14 GAAP, $1.43 adj; raises FY adj EPS view to $4.90+
Q2 sales $11.3B (+10.1% reported, +14.3% organic); GAAP EPS $1.14, adjusted EPS $1.43 (+22.2%).
Abbott shareholders elect all 12 directors, reject 5 shareholder proposals at annual meeting
All 12 board nominees elected; Ernst & Young ratified as auditor with 99.3% votes for.
Abbott Q1 sales $11.9B (+13.8%), adjusted EPS $1.73; full-year guidance reaffirmed
Q1 sales $11.9B, +13.8% reported, +17.5% organic; GAAP EPS $1.37, adjusted EPS $1.73.
Abbott reduces board size from 13 to 12 effective April 29, 2022
Board amended by-laws to set board size at 12 directors, down from 13.
Abbott recalls Similac infant formula from Sturgis MI plant; reaffirms EPS guidance
Proactive voluntary recall of Similac powder infant formulas from Sturgis, MI facility; primarily US and Canada.
Abbott Q4 revenue $11.5B, adj EPS $1.32; FY2022 adj EPS guidance at least $4.70
Q4 2021 GAAP diluted EPS $1.11; adjusted diluted EPS $1.32; sales $11.5B (+7.2% reported, +7.7% organic).
Abbott director Roxanne S. Austin will not stand for re-election in 2022
Roxanne S. Austin informed Abbott Labs board on Dec 9, 2021 of her decision not to seek re-election.
Abbott names CEO Robert B. Ford as Chairman; Miles D. White retires
Miles D. White resigns as Executive Chairman and director, effective Dec 10, 2021.
Abbott Q3 sales $10.9B (+23.4%); adj. EPS $1.40 (+42.9%); raises FY guidance
GAAP diluted EPS $1.17; adjusted diluted EPS $1.40, up 42.9% vs 3Q20.
Abbott appoints Patricia P. Gonzalez to Board of Directors; board size increased to 14
Patricia P. Gonzalez named to Abbott Laboratories Board of Directors effective August 30, 2021.
On April 25, 2025, Hubert L. Allen, Executive Vice President, General Counsel and Secretary, informed Abbott Laboratories that he plans to retire from the company after a period of transition.
Robert E. Funck, Jr., Executive Vice President, Finance, informed Abbott Laboratories that he plans to retire from the company after 36 years of service, effective July 1, 2024.
On September 15, 2022, Claire Babineaux-Fontenot was named to the Abbott Laboratories’ (“Abbott”) Board of Directors.
On December 9, 2021, Roxanne S. Austin informed the Abbott Laboratories Board of Directors of her decision not to stand for re-election at the end of her current term expiring at the 2022 annual shareholders meeting in April.
On December 10, 2021, Abbott’s Board of Directors appointed Robert B. Ford, Abbott’s President and Chief Executive Officer and a director, to the additional position of Chairman of the Board, effective upon Mr. White’s resignation.
Miles D. White informed the Abbott Laboratories (“Abbott”) Board of Directors that he will step down as Executive Chairman of the Board and as a director, effective December 10, 2021.
On August 30, 2021, Patricia P. Gonzalez was named to the Abbott Laboratories’ (“Abbott”) Board of Directors.
Max materiality 1.00 · Median 0.70 · Most common event earnings